- Home
- NXTC vs NAII Comparison
NXTC vs NAII Comparison
Compare NXTC & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- NAII
- Stock Information
- Founded
- NXTC 2015
- NAII 1980
- Country
- NXTC United States
- NAII United States
- Employees
- NXTC N/A
- NAII N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- NAII Medicinal Chemicals and Botanical Products
- Sector
- NXTC Health Care
- NAII Health Care
- Exchange
- NXTC Nasdaq
- NAII Nasdaq
- Market Cap
- NXTC 31.6M
- NAII 28.0M
- IPO Year
- NXTC 2019
- NAII 1987
- Fundamental
- Price
- NXTC $0.89
- NAII $4.15
- Analyst Decision
- NXTC Strong Buy
- NAII
- Analyst Count
- NXTC 2
- NAII 0
- Target Price
- NXTC $4.00
- NAII N/A
- AVG Volume (30 Days)
- NXTC 218.5K
- NAII 9.7K
- Earning Date
- NXTC 11-07-2024
- NAII 02-11-2025
- Dividend Yield
- NXTC N/A
- NAII N/A
- EPS Growth
- NXTC N/A
- NAII N/A
- EPS
- NXTC N/A
- NAII N/A
- Revenue
- NXTC N/A
- NAII $112,977,000.00
- Revenue This Year
- NXTC N/A
- NAII N/A
- Revenue Next Year
- NXTC N/A
- NAII N/A
- P/E Ratio
- NXTC N/A
- NAII N/A
- Revenue Growth
- NXTC N/A
- NAII N/A
- 52 Week Low
- NXTC $0.87
- NAII $4.11
- 52 Week High
- NXTC $2.57
- NAII $7.26
- Technical
- Relative Strength Index (RSI)
- NXTC 22.88
- NAII 39.86
- Support Level
- NXTC $1.06
- NAII $4.20
- Resistance Level
- NXTC $1.21
- NAII $4.33
- Average True Range (ATR)
- NXTC 0.10
- NAII 0.14
- MACD
- NXTC -0.02
- NAII -0.01
- Stochastic Oscillator
- NXTC 5.21
- NAII 0.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About NAII Natural Alternatives International Inc.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.